Unlike basic APIs that expose only candidate and job data, Tracker's new API provides complete operational coverage. Partners and customers can build secure, purpose-built integrations across the ...

In cybersecurity, we live by our metrics. We measure Mean Time to Respond (MTTR), Dwell Time, and Patch Cadence. These numbers tell the Board how fast we react when things go wrong.But in the era of ...

Radware is strengthening its API security platform with the acquisition of Pynt, a provider of API security testing tools as part of an effort to extend the Radware's API Security Service.

A hands-on test compared Visual Studio Code and Google Antigravity on generating and refining a simple dynamic Ticket Desk ...

As AI agents code alongside humans, API platforms and DevRel must redesign for machine-first consumption.

Abstract: Today’s cloud native applications are often built using a service-oriented architecture supported by many microservices hosted using serverless Function-as-a-Service (FaaS) platforms. The ...

OpenAI announced it will begin testing ads within ChatGPT in the coming weeks. Ads will begin to appear at the bottom of the chatbot's answers, and they will be clearly labeled, OpenAI said. OpenAI ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead toward regulatory filings for the novel HIV regimen. In Gilead's ...

Cdymax Pharma has been slapped with a warning letter from the FDA outlining two observations against the Bangalore, India-based API maker, both linked to testing shortfalls. The letter comes in ...

Good morning, and welcome to the Agios Pharmaceuticals Investor Conference Call and Webcast. [Operator Instructions] Please be advised that this call is being recorded at Agios' request. I would now ...

tests/ ├── __init__.py ├── conftest.py # Shared fixtures and API client ├── pytest.ini # Pytest configuration ├── test_models.py # Models endpoints (3 tests) ├── test_model.py # Model-specific ...

Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer. The biopharma evaluated the Bristol Myers Squibb-partnered ...